



**2. APPROVAL OF MINUTES OF PREVIOUS MEETING**

Upon motion duly made and seconded, the minutes of the meeting of December 13, 2017 were approved, Regents Lansing, Makarechian, Reiss, and Sherman voting “aye.”<sup>1</sup>

**3. REMARKS OF THE EXECUTIVE VICE PRESIDENT – UC HEALTH**

[Background material was provided to the Committee in advance of the meeting, and a copy is on file in the Office of the Secretary and Chief of Staff.]

Due to time constraints at this meeting, Executive Vice President Stobo stated that he would refrain from presenting remarks.

**4. FORMALIZE APPROVAL OF BENCHMARKING FRAMEWORK FOR UC HEALTH POSITIONS RESULTING IN REVISIONS TO THE RESPECTIVE MARKET REFERENCE ZONES**

The President of the University recommended that the Health Services Committee approve the new Benchmarking Framework revising the Market Reference Zones for UC Health positions in the Senior Management Group, recommended by the Regents Workgroup on UC Health Executive Compensation and approved by the Regents’ Governance and Compensation Committee, as shown in Attachment 1.

[Background material was provided to the Committee in advance of the meeting, and a copy is on file in the Office of the Secretary and Chief of Staff.]

Committee Chair Lansing recalled that the Committee had already discussed this item in March 2017.

Upon motion duly made and seconded, the Committee approved the President’s recommendation, Regents Lansing, Makarechian, Reiss, and Sherman voting “aye.”

**5. UC HEALTH UPDATE ON CAR-T CELL THERAPY**

[Background material was provided to the Committee in advance of the meeting, and a copy is on file in the Office of the Secretary and Chief of Staff.]

Chancellor Hawgood introduced cancer biologist Alan Ashworth, President of the UCSF Helen Diller Family Comprehensive Cancer Center, Senior Vice President for Cancer Services, and Professor of Medicine. Before joining UCSF in 2015, Mr. Ashworth had served as the Chief Executive of the Institute of Cancer Research, London, and was perhaps best known for being part of the team that in 1995 identified the BRCA2 gene as a cancer susceptibility gene. Ten years later, he used a concept known as synthetic lethality to develop a new class of cancer drugs, PARP inhibitors, which had been successful in the

---

<sup>1</sup> Roll call vote required by the Bagley-Keene Open Meeting Act [Government Code § 11123(b)(1)(D)] for all meetings held by teleconference.

























